Webinar
Digital transformation in pathology
How an AI enabled solution for microsatellite instability (MSI) screening can modernize and potentially optimize pathology workflows
Date: May 9th | 5pm CET | Duration: 1 hour


Discover the latest research into MSI and learn about MSIntuit™ CRC, a novel AI pre-screening approach for colorectal cancer.
The discussion will also cover :
- The need and opportunities for digitization in pathology.
- AI methodologies that promote confidence in using these tools in clinical routine.
- A use case for AI augmentation: MSI pre-screening in colorectal cancer.
- In-region applications: implications of the adoption of such technology in Spain.
Panelists
.png?width=2663&height=2841&name=Jacob%20Kather%20updated-min%20(1).png)
Jakob Nikolas Kather
Professor of Clinical Artificial Intelligence, Else Kröner Fresenius Center for Digital Health at Technical University Dresden, Germany

Magali Svrcek
International expert in GI pathology. Professor at Saint Antoine Hospital, France

Javier Hernandez Losa
Director of Molecular Biology Laboratory, Pathology Department at Vall d’Hebron University Hospital, Barcelona, Spain

Charlie Saillard
Senior Data Scientist
Medical imaging at Owkin

Jakob Nikolas Kather
Professor of Clinical Artificial Intelligence, Else Kröner, Fresenius Center for Digital Health at Technical University Dresden, Germany
Jakob is a physician scientist with board certification in internal medicine. He was recently appointed professor of Clinical Artificial Intelligence at Technical University Dresden, Germany. His interdisciplinary research team is working at the interface of computer science and precision oncology. They are building and validating new AI-based biomarkers. The team is guided by a vision: physicians are trained in data science and researchers from computer science or technical subjects learn to identify and solve relevant clinical problems. In the last year, the team's research studies were published in Nature Medicine and Nature Cancer, among other venues.
Magali Svrcek, MD, PhD
International expert in GI pathology, Professor at Hospital Saint Antoine, France
Magali is a professor at the Saint-Antoine Hospital in Paris. Her research focuses on digestive pathology and molecular biology. She is international expert in gastro-intestinal pathology, including inflammatory bowel diseases, colorectal, gastric and pancreatic cancers. She is a member of the research group “Microsatellite Instability and Cancers” (Centre de Recherche Saint-Antoine, Paris, France). She is also a member of Member of the AP-HP Cancer group from 2021 and other European and international working groups and networks (e.g. H-ECCO, European Consortium Care for CMMRD, International HDGC Consortium, EORTC Gastrointestinal Tract Cancer and Endocrine Tumors Groups, Gastrointestinal Pathology Working Group at ESMO). She has worked with Owkin for the development and integration of MSIntuit CRC, an artificial intelligence solution for routine dMMR/MSI diagnosis (2021).
Javier Hernandez Losa
Director of Molecular Biology Laboratory, Pathology Department at Vall d’Hebron University Hospital, Barcelona, Spain
Javier has trained in cancer research, focusing on the signaling and virus detection pathways in paraffinized human samples at the Department of Pathology in Puerta de Hierro Hospital (Madrid) and later at the Vall d'Hebron University Hospital (Barcelona). He currently is the Director of the Molecular Biology Laboratory within the Department of Pathology, endorsing extensive experience in the field of biomarkers, being today one of the reference laboratories in Spain in Molecular pathology. Thanks to these Molecular analyses based on time PCR Real and NGS have contributed to the selection of patients for the different clinical trials carried out at our institution. In addition, in the last five years, the laboratory has validated more than 20 prognostic and/or predictive cancer markers by immunohistochemical techniques. Recently, Dr. Hernández-Losa has shown to have experience in the study of drugs in different in vitro models of breast and pancreatic cancer and the development of new markers. Finally, Dr. Hernández-Losa has been the director of 3 doctoral theses, and 10 Master's works and is the author of more than 100 international peer-review publications.
Charlie Saillard
Senior Data Scientist, Medical Imaging at Owkin
Charlie obtained a degree in Applied Mathematics at Université Paris Dauphine and graduated from Ecole Normale Supérieure. He is now a Senior Data Scientist at Owkin, focusing on the analysis of pathology slides using deep learning. Over the past five years, Charlie has co-authored 16 publications, some of which have been published in high-impact journals such as Hepatology and Nature Communications or prestigious medical conferences such as ASCO and ESMO. He has also led the development and validation of MSIntuit CRC, an AI-based pre-screening tool for microsatellite instability in colorectal cancer.
MSIntuit CRC is a medical device for use by healthcare professionals only. This deep learning software is intended for assisting pathologists in the pre-selection of patients with a stable microsatellite phenotype (MSS) / proficient mismatch repair system (pMMR) associated with primary colorectal cancer. It identifies MSS patients from a digitized histology slide image file of hematoxylin and eosin (HE) stained colorectal tissue resection for patients with primary colorectal cancer. MSIntuit CRC is intended to be used as an additional source of information and its results should not be used as the primary diagnosis. Pathologists should only use MSIntuit CRC in conjunction with their usual diagnostic criteria. MSIntuit CRC is CE-IVD marked for diagnostic use. For use only in countries with applicable health authority registrations (France & United Kingdom).
For detailed information on proper use and precautions, please read carefully the instructions of use provided with the product or contact Owkin.
Manufacturer: Owkin France. MSIntuit is a trademark of Owkin Inc (patent info to add).
Information updated on March 31st 2023.